A Study to Test a Measure of Symptoms of Older Men With Low Testosterone On and Off Testosterone Replacement Treatment (P05815)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two Period Cross Over Trial to Validate Patient-Reported Outcome Measures for Use in Men With Late Onset Hypogonadism
Sponsor: Merck Sharp & Dohme LLC
Terminated
Recruitment issues
Other terminated trials from Merck Sharp & Dohme LLC
- Melanoma · Phase PHASE2 · Feb 2026
- Advanced Solid Tumor · Phase PHASE2 · Jan 2026
- Lung Cancer Metastatic · Phase PHASE1/PHASE2 · Dec 2025
- Advanced and Metastatic Urothelial Cancer · Phase PHASE2 · Sep 2025
- Malignant Solid Tumor · Phase PHASE1 · Aug 2025
More terminations from Merck Sharp & Dohme LLC
Other Hypogonadism trials with similar outcome
This PHASE2 trial investigates Hypogonadism and is currently terminated or withdrawn. Merck Sharp & Dohme LLC leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jun 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jun 2022 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Jul 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.